Denali Therapeutics Announces $200M Public Offering

Denali Therapeutics ( (DNLI) ) has shared an update.

On December 9, 2025, Denali Therapeutics entered into an underwriting agreement with major financial institutions for a public offering of its common stock and pre-funded warrants, aiming to raise approximately $200 million, potentially increasing to $230 million if additional shares are purchased. The offering is set to close on December 11, 2025, and is expected to strengthen Denali’s financial position, enhancing its ability to advance its therapeutic candidates and potentially impacting its market positioning in the biotechnology industry.

The most recent analyst rating on (DNLI) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Denali Therapeutics stock, see the DNLI Stock Forecast page.

Spark’s Take on DNLI Stock

According to Spark, TipRanks’ AI Analyst, DNLI is a Neutral.

Denali Therapeutics faces significant financial hurdles with declining revenues and profitability issues, reflected in poor financial and valuation scores. Technical indicators also suggest a bearish trend. Positive corporate events, such as the BLA submission, offer a potential growth catalyst but are balanced by setbacks like the discontinued ALS trial. The overall outlook remains challenging, with strategic adjustments needed for improvement.

To see Spark’s full report on DNLI stock, click here.

More about Denali Therapeutics

Denali Therapeutics is a biotechnology company focused on developing biotherapeutics that can cross the blood-brain barrier using its proprietary TransportVehicle™ platform. The company is dedicated to creating effective treatments for neurodegenerative, lysosomal storage, and other serious diseases.

Average Trading Volume: 1,717,785

Technical Sentiment Signal: Buy

Current Market Cap: $2.89B

For an in-depth examination of DNLI stock, go to TipRanks’ Overview page.